NGM — NGM Biopharmaceuticals Share News
0.000.00%
Last trade - 00:00- $128.53m
- -$15.65m
- $4.42m
Brief: NGM Bio Announces Pricing Of Upsized $125 Mln Public Offering Of Common Stock
Brief: NGM Bio Announces Proposed Offering Of Common Stock
Brief: NGM Discloses Third Oncology Development Candidate, Ngm438
Brief: NGM Bio Presents Phase 1 Safety And Pharmacokinetics Data For NGM621
Brief: NGM Bio Reports Q3 2020 Financial Results
Brief: NGM Biopharmaceuticals Inc Expands Oncology Portfolio With First Immuno-Oncology Development Candidate, Ngm707
Brief: NGM Bio Presents Findings From 24-Week Phase 2 Study (Cohort 4) Of Aldafermin And Announces Enrollment Completed In Phase 2B Alpine 2/3 Study
Brief: NGM Bio Reports Qtrly Loss Per Share Of $0.38
Brief: NGM Bio Initiates Phase 2 Study Of NGM621 In AMD Patients
Brief: Ngm Biopharmaceuticals Files Prospectus Related To Offering Of Common Stock Of Upto $150 Mln - SEC Filing
Brief: NGM Biopharmaceuticals Files For Mixed Shelf Of Upto $400 Million
Brief: NGM Bio Appoints Siobhan Nolan Mangini As CFO
Brief: NGM Biopharmaceuticals Posts Quarterly Loss Per Share $0.28
Intercept, NGM rise on rival Novo's mixed NASH drug data
Brief: NGM Bio Reports Q4 Net Loss Per Share Of $0.24
NASDAQ RESUMED AT 09:40 AM
NGM Biopharma: Surges on positive NASH trial drug results
NASDAQ RESUMED AT 08:30 AM
Brief: NGM Bio Announces Positive Preliminary Topline Liver Histology And Biomarker Data From 24-Week Phase 2 Study Of Aldafermin In Nash Patients